GTSIF

Greenstar Biosciences Corp.

Lobe Sciences Announces Data Demonstrating That Its Combination Therapeutic Candidates are Significantly More Effective Than Monotherapy in mTBI and PTSD

Combination Therapy with Psilocybin plus NAC (N-Acetylcysteine) Is Statistically Significantly Better Than Either Agent Alone or Placebo in a Rodent Model of mTBI and PTSD VANCOUVER, BC, Sept. 28, 2021 - Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE: LOBE) (OTC Pink: GTSIF) is pleased to announce interim data from its preclinical rese... Read More...

Lobe Sciences Appoints Gilberto Jesรบs Mendoza, President of the World Boxing Association, to Advisory Board

Vancouver, British Columbia--(Newsfile Corp. - July 13, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the appointment of Gilberto Jesรบs Mendoza, President of the World Boxing Association, to its Advisory Board.Philip Young, CEO and Director of Lobe stated, "We are privileged to w... Read More...

Lobe Sciences Secures Production and Supply Agreement for Vitamind Consumer Packaged Goods Products

Natural health products will be manufactured and packaged by HAVN LifeVancouver, British Columbia--(Newsfile Corp. - May 19, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce it has entered into a production and supply agreement (the "Agreement") on May 14, 2021 with HAVN Life Scienc... Read More...

Lobe Sciences Announces Further Upsizing and Second Closing of Non-Brokered Private Placement

Vancouver, British Columbia--(Newsfile Corp. - January 6, 2021) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce, that due to strong investor demand, it has further upsized its previously announced non-brokered private placement of units (the "Units") from $2,700,000 to $3,445,847 (the "O... Read More...

Lobe Sciences Announces Jonathan Gilbert Appointed Executive Chairman of the Board of Directors

Appointment of Jonathan Gilbert as Executive Chairman allows Lobe to capitalize on his significant capital markets experienceVancouver, British Columbia--(Newsfile Corp. - December 14, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that the appointment of Mr. Jonathan Gilbert as E... Read More...

Lobe Sciences Commences Engineering of Nasal Mist Device

Vancouver, British Columbia--(Newsfile Corp. - December 3, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it has engaged VisionWorks Engineering of San Diego, CA to commence engineering work to complete and test a proof of concept prototype of its nasal mist device.This is a ... Read More...

Lobe Sciences Announces CAD$23,000,000 Sale of Cowlitz Cannabis Option to Ionic Brands Corp.

Signed LOI for CAD$23 million sale to Ionic provides shareholder valueVancouver, British Columbia--(Newsfile Corp. - December 1, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce that it has received and signed a non-binding letter of intent dated November 30, 2020 with IONIC Brands ... Read More...

Lobe Sciences Announces Launch of Preclinical Study in Collaboration with the University of Miami Miller School of Medicine

Vancouver, British Columbia--(Newsfile Corp. - November 30, 2020) - Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) ("Lobe" or the "Company") is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine ("NAC") for the treatment of mild traumatic brain injury/concussion ("mTBI") with post-trauma... Read More...